|
|
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- NHS Trusts (England) - Chief Executive
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- Special Health Authorities
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- GP - Locum
- NHS 111 and Out of hours providers
- GP Practices
- DHSC Supply Disruption - Medicines
- Community Pharmacy
- Primary Care Networks
|
| Title: |
|
Azithromycin in the Management of COVID-19 (SARS-CoV-2)
|
| Broadcast content: |
|
It is now recommended that azithromycin should NOT used in the management of confirmed or suspected COVID-19 infection in hospitalised patients unless there are additional indications for which its use remains appropriate (see Product Details). Within primary care the use of azithromycin and other antimicrobials, specifically in the treatment of COVID-19 infection, should be solely within the context of a trial. Please see attached alert for more details.
|
| Additional information: |
|
NHS England and NHS Improvement Offices please cascade to Community pharmacy
|